DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for histiocytic sarcoma — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleHistiocytic sarcoma maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for histiocytic sarcoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
tumor protein p53 (TP53) — TP53 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9R2Q · 3.2 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
An 8-year-old girl with histiocytic sarcoma was successfully treated with an abbreviated high-risk leukaemia chemotherapy regimen, reported in 2014. A 4-year-old patient treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy had been disease-free for six years at the time of the 2018 report. Two cases of primary histiocytic sarcoma of the brain were described in 2022, with varied clinical presentation and pathological findings; the authors noted that prognosis is very poor and that no consensus on treatment exists, mainly because of the disease's rarity.
The 2014 case report states that true histiocytic sarcoma is exceedingly rare in paediatric patients, that the tumours are frequently aggressive, and that outcome has traditionally been poor. The 2018 report describes histiocytic sarcoma as an extremely rare tumour in children that may occur sporadically or in association with other haematological malignancies; it arises most commonly in lymph nodes but can occur anywhere, and clinical presentation is usually with advanced disease. The 2022 paper notes that central nervous system involvement is rare, with around 30 cases reported in English literature, and that morphological and immunohistochemical evidence of histiocytic differentiation is essential for diagnosis.
All three papers are case reports or small case series. There is no standard chemotherapy regimen, no randomised trial, and no prospective data. The 2014 and 2018 reports describe individual successes, but the 2022 paper reiterates that prognosis is very poor and treatment consensus is absent. What is still missing is any large-scale or controlled evidence, a standardised treatment protocol, and a way to stratify patients by disease site or molecular features. Funding for multi-centre trials in such a rare disease remains the fundamental gap.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Pediatric Blood & Cancer · 2014 · 19 citations
Successful treatment of pediatric histiocytic sarcoma using abbreviated high-risk leukemia chemotherapy
AbstractHistiocytic sarcoma (HS) is a malignant tumor composed of proliferating cells of histiocytic origin. True HS is exceedingly rare, particularly in pediatric patients. These tumors are frequently aggressive, and outcome for patients with HS has traditionally been poor. There is currently no consensus on the optimal management of these tumors, with the literature consisting largely of case reports and small case series utilizing a wide variety of therapies. We describe a case of HS in an 8-year-old female who was successfully treated with an abbreviated leukemia chemotherapy regimen.
Histiocytic sarcoma in a child—successful management and long‐term survival with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
AbstractHistiocytic sarcoma is an extremely rare tumor in children. It may occur sporadically or in association with other hematological malignancies. It arises most commonly in the lymph nodes but may occur anywhere in the body and clinical presentation is usually with advanced disease. Following tissue diagnosis and staging, management is with chemotherapy though there are no standard regimes. Surgery has been used successfully for local control. This is the first description of the use of peritonectomy and hyperthermic intraperitoneal chemotherapy to treat histiocytic sarcoma. The 4-year-old patient has been disease free for 6 years.
Neurology India · 2022 · 5 citations · open access
Primary Histiocytic Sarcoma of Brain—Illustration of Two Cases with Varied Histomorphological Features
AbstractHistiocytic sarcoma (HS) is an aggressive hematolymphoid malignancy that arises from non Langerhans histiocytes and usually involves the skin, lymph nodes, and intestine. The involvement of the central nervous system (CNS) is a rare occurrence with around 30 cases being reported in English literature. Morphological and immunohistochemical evidence of histiocytic differentiation is essential for diagnosis. Prognosis is very poor and consensus on treatment is not available mainly due to its rarity. We report two cases of HS with varied clinical presentation and pathological findings and elucidate the diagnostic challenges of this rare entity.
Clinical Case Reports · 2025 · 0 citations · open access
Misdiagnosed Histiocytic Sarcoma: A Case Report
AbstractWe report a 31-year-old male patient repeatedly hospitalized for mimicking infectious symptoms. Following standardized anti-infective and anti-inflammatory treatment, clinical evolution was discordant, characterized by treatment non-response and symptom exacerbation. Ultimately, the multidisciplinary team and repeated histopathological examinations diagnosed histiocytic sarcoma (HS). Unfortunately, the treatment opportunity was lost due to HS's high aggressiveness and rapid progression.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
